Page 5 - CAR-T Brochure 2024

How is CAR-T therapy administered?
• CAR-T infusions may be done inpatient or outpatient. But in either case, the patient must be closely monitored.
• The infusion usually takes less than an hour.
• After receiving CAR-T therapy, patients will be monitored closely for the next few weeks for any toxic reactions that may occur when CAR-T cells are rapidly expanding and killing the cancer.
How well does CAR-T therapy work for CLL?
• As many as 95% of CLL patients responded to CAR-T therapy in clinical trials.
• Up to 86% achieved a deep remission with no detectable CLL, also called undetectable measurable residual disease (uMRD). Among these patients, the responses can be very long-lived.
What are some advantages of CAR-T therapy in CLL?
• CAR-T therapy removes some of the risks that come with transplanting someone else’s immune cells via bone marrow
transplant such as the condition known as graft versus host disease. This potentially life-threatening complication can occur when the transplanted stem cells from another person attack their new host, the patient receiving them.
• CAR-T therapy is the ultimate short-duration therapy because it is a single infusion that can provide many years of remission.